# Assessing Tenapanor as a Treatment of CF-related Constipation.

> **NCT06810167** · PHASE3 · RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 25 (estimated)

## Conditions studied

- Cystic Fibrosis
- Constipation

## Interventions

- **DRUG:** Tenapanor

## Key facts

- **NCT ID:** NCT06810167
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-01
- **Primary completion:** 2026-06-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-03-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06810167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06810167, "Assessing Tenapanor as a Treatment of CF-related Constipation.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06810167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*